Based on this classification we chose several DNA sequence alterations, such as IDH1/2, H3-3A, ATRX, CDKN2A/B, 1p/19q-codeletion, TERT, MGMT, EGFR, that can be used as targets for diagnosis and evaluation of therapeutic response, as well as potential targets for successful treatment of glioma (Śledzińska et al., 2021; Miller, 2022; Yang et al., 2022). This evidence concerns the gene EGFR and central nervous system cancer.